New technologies for influenza vaccines

Dormitzer, Philip R.; Tsai, Theodore F.; Giudice, Giuseppe Del

doi:10.4161/hv.8.1.18859

Cited by 47 publications

(41 citation statements)

References 169 publications

(190 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In split virus vaccines, the virus has been disrupted by a detergent. While in subunit vaccines, HA and NA have been further purified by removal of other internal viral components which is related to immunogenicity and protective efficacy of influenza vaccine [14], [15]. Reverse genetics, used to generate influenza virus from cells co-transfected with plasmids carrying individual influenza virus genes, has been used in vaccine development since 1996 [6], [16]–[18].…”

Section: Discussionmentioning

confidence: 99%

Response of Mice and Ferrets to a Monovalent Influenza A (H7N9) Split Vaccine

Duan

Chen

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

In early spring 2013, the emergence of the influenza A (H7N9) virus in humans in Eastern China raised concerns of a new influenza pandemic. Development of a safe and effective H7N9 influenza vaccine is urgently needed. To this end, we first synthesized the hemagglutinin (HA) and neuraminidase (NA) genes of the influenza A (H7N9) virus A/AnHui/1/2013. Using reverse genetics, we rescued a reassortant virus (H7N9/PR8) that contained the HA and NA genes from wild-type H7N9 and six genes encoding internal proteins from the A/Puerto Rico/8/34 (PR8) virus. Next, the pathogenicity of the reassortant virus was evaluated both in vivo and in vitro. We found that the virus was non-pathogenic in mice and was stable after serial passaging in eggs. Furthermore, we found that a monovalent influenza A (H7N9) split vaccine prepared from the virus was immunogenic in mice and ferrets. When given intramuscularly, the vaccine (two doses of at least 15-µg) completely protected mice from normally lethal wild-type H7N9 virus challenge. In summary, our H7N9 vaccine, developed over a short time, is a potential candidate for further clinical evaluation and human use.

show abstract

Section: Discussionmentioning

confidence: 99%

Response of Mice and Ferrets to a Monovalent Influenza A (H7N9) Split Vaccine

Duan

Chen

et al. 2014

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…A few adjuvanted influenza vaccines are licensed in Europe and a growing number of other candidates are undergoing preclinical and clinical development. 13,15 In addition, the use of cell culture-derived vaccines could reduce the dependency on cumbersome egg-based manufacturing processes and potentially offer other advantages such as shortened production time. 32 The aims of the studies in this report were to evaluate the potential of a cationic liposome-based adjuvant, Vaxfectin ® , to increase the humoral and cell-mediated immune responses to seasonal, split trivalent and pandemic, whole virus monovalent influenza vaccines produced by Vero cell culture.…”

Section: Discussionmentioning

confidence: 99%

“…10,11 Adjuvants are designed to stimulate innate immune responses which consequently increase adaptive immune responses such as antibody and T-cell responses; they may also facilitate antigen and/or dose sparing. [12][13][14][15] Recent randomized controlled trials testing squalene-based oil-in-water adjuvant formulations such as MF-59 or AS03 revealed significantly enhanced efficacy in children or significantly enhanced immunogenicity in children and in adults, including those ≥ 65 y old. [16][17][18] Adjuvanted influenza vaccines may be critical to overcoming the limitations of immunosenescence in the elderly 19,20 as well as augmenting immune responses to poorly-immunogenic hemagglutinins such as H5 21 in all age groups; adjuvants are required for H5N1 vaccines to achieve robust HI responses.…”

mentioning

confidence: 99%

Preclinical evaluation of Vaxfectin^®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines

Smith

Wodal

Crowe

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…to mice induced strong M1-specific humoral and cellular immune responses and completely protected mice against challenge with a homologous virus A/chicken/Jiangsu/7/02 (H9N2) and partially protected against challenge with heterosubtypic viruses [A/PR/8/34 (H1N1) or A/chicken/Henan/12/04 (H5N1)]. In a Phase I clinical trial, a chitosan formulated inactivated trivalent seasonal influenza vaccine was well tolerated and induced a four-fold or greater increase in HI antibody titers against seasonal influenza viruses in more than 40% of the volunteers[94]. …”

Section: Enhancing Vaccine Efficacy Using Adjuvantsmentioning

confidence: 99%

Vaccine approaches conferring cross-protection against influenza viruses

Vemula

Sayedahmed

Sambhara

et al. 2017

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction Annual vaccination is one of the most efficient and cost-effective strategies to prevent and control influenza epidemics. Most of currently available influenza vaccines are strong inducer of antibody responses against viral surface proteins, hemagglutinin (HA) and neuraminidase (NA), but are poor inducers of cell-mediated immune responses against conserved internal proteins. Moreover, due to the high variability of viral surface proteins because of antigenic drift or antigenic shift, many of the currently licensed vaccines confer little or no protection against drift or shift variants. Areas covered Next generation influenza vaccines that can induce humoral immune responses to receptor-binding epitopes as well as broadly neutralizing conserved epitopes, and cell-mediated immune responses against highly conserved internal proteins would be effective against variant viruses as well as a novel pandemic influenza until circulating strain-specific vaccines become available. Here we discuss vaccine approaches that have potential to provide broad spectrum protection against influenza viruses. Expert opinion Based on current progress in defining cross-protective influenza immunity, it seems that the development of a universal influenza vaccine is feasible. It would revolutionize the strategy for influenza pandemic preparedness, and significantly impact the shelf-life and protection efficacy of seasonal influenza vaccines.

show abstract

New technologies for influenza vaccines

Cited by 47 publications

References 169 publications

Response of Mice and Ferrets to a Monovalent Influenza A (H7N9) Split Vaccine

Response of Mice and Ferrets to a Monovalent Influenza A (H7N9) Split Vaccine

Preclinical evaluation of Vaxfectin^®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines

Vaccine approaches conferring cross-protection against influenza viruses

Contact Info

Product

Resources

About

New technologies for influenza vaccines

Cited by 47 publications

References 169 publications

Response of Mice and Ferrets to a Monovalent Influenza A (H7N9) Split Vaccine

Response of Mice and Ferrets to a Monovalent Influenza A (H7N9) Split Vaccine

Preclinical evaluation of Vaxfectin®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines

Vaccine approaches conferring cross-protection against influenza viruses

Contact Info

Product

Resources

About

Preclinical evaluation of Vaxfectin^®-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccines